Abstract
BackgroundWeissella cibaria CMU (oraCMU) has been commercially available in the market for several years as oral care probiotics. The present study aimed to evaluate the effects of oraCMU-containing tablets on periodontal health and oral microbiota.MethodsA randomised, double-blind, placebo-controlled trial was conducted in 92 adults without periodontitis (20–39 years of age). All subjects received dental scaling and root planing, and were randomly assigned to either probiotic or placebo groups. The tablets were administered once daily for 8 weeks. Periodontal clinical parameters included bleeding on probing (BOP), probing depth (PD), gingival index (GI), and plaque index (PI). In addition, microbiota in the gingival sulcus were analysed.ResultsBOP improved more in the probiotic group over 8 weeks. There were statistically significant differences in BOP of the maxilla buccal and lingual sites between the groups during the intervention (P < 0.05). No significant inter-group differences in PD, GI, and PI were observed during the intervention. Oral bacteria were observed to be fewer in the probiotic group. There was a significant change in levels of Fusobacterium nucleatum at four and 8 weeks between the two groups. Besides, there were significant differences at 8 weeks in levels of Staphylococcus aureus.ConclusionsWe reported an improvement in BOP and microbial environment and demonstrated the antimicrobial activity of oraCMU against F. nucleatum. Thus, its supplementation may contribute to overall oral health.Trial registrationEthical issues approved by the Kangwon National University Institutional Review Board with a number of KWNUIRB-2018-05-003-005 and CRIS code Number of KCT0005078 were retrospectively registered on 06/02/2020. This study was conducted in the period of July to November 2018.
Highlights
Weissella cibaria CMU has been commercially available in the market for several years as oral care probiotics
Participants were informed that refusal to participate would not disadvantage them in any way, and they were free to withdraw from the study at any time
Probiotics refer to live bacteria that are beneficial to the host when ingested at an appropriate amount [7]
Summary
Weissella cibaria CMU (oraCMU) has been commercially available in the market for several years as oral care probiotics. Periodontal disease is a plaque-related infectious disease caused by pathogenic biofilm accumulating on the dental surface and oral mucosa. It is considered one of the most common chronic diseases worldwide, is caused by plaque-related bacteria, and is a major cause of tooth loss [2]. Changes in bacterial distribution occur when normal gingival sulcus transforms into pathological periodontal pockets. These bacteria have various pathogenic properties that colonise the gingival space, evade the defence system of the host, and damage tissues [4]. Probiotics might be advantageous in preventing or treating oral diseases such as caries, gingivitis, or periodontitis by improving the environment of oral microbiota in the oral cavity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
